These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 11038166)
1. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Jacobsen W; Kuhn B; Soldner A; Kirchner G; Sewing KF; Kollman PA; Benet LZ; Christians U Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166 [TBL] [Abstract][Full Text] [Related]
2. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499 [TBL] [Abstract][Full Text] [Related]
3. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Prueksaritanont T; Subramanian R; Fang X; Ma B; Qiu Y; Lin JH; Pearson PG; Baillie TA Drug Metab Dispos; 2002 May; 30(5):505-12. PubMed ID: 11950779 [TBL] [Abstract][Full Text] [Related]
4. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Park JE; Kim KB; Bae SK; Moon BS; Liu KH; Shin JG Xenobiotica; 2008 Sep; 38(9):1240-51. PubMed ID: 18720283 [TBL] [Abstract][Full Text] [Related]
5. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579 [TBL] [Abstract][Full Text] [Related]
6. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Black AE; Sinz MW; Hayes RN; Woolf TF Drug Metab Dispos; 1998 Aug; 26(8):755-63. PubMed ID: 9698289 [TBL] [Abstract][Full Text] [Related]
7. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412 [TBL] [Abstract][Full Text] [Related]
8. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Backman JT; Luurila H; Neuvonen M; Neuvonen PJ Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850 [TBL] [Abstract][Full Text] [Related]
9. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Lau YY; Okochi H; Huang Y; Benet LZ Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870 [TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Jacobson TA Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608 [TBL] [Abstract][Full Text] [Related]
13. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Goosen TC; Bauman JN; Davis JA; Yu C; Hurst SI; Williams JA; Loi CM Drug Metab Dispos; 2007 Aug; 35(8):1315-24. PubMed ID: 17470524 [TBL] [Abstract][Full Text] [Related]
14. Interaction between several medicines and statins. Fujino H; Saito T; Tsunenari Y; Kojima J Arzneimittelforschung; 2003; 53(3):145-53. PubMed ID: 12705168 [TBL] [Abstract][Full Text] [Related]
15. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896 [TBL] [Abstract][Full Text] [Related]
16. DFT study on hydroxy acid-lactone interconversion of statins: the case of atorvastatin. Hoffmann M; Nowosielski M Org Biomol Chem; 2008 Oct; 6(19):3527-31. PubMed ID: 19082153 [TBL] [Abstract][Full Text] [Related]
17. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Mc Donnell CG; Shorten G; Van Pelt FN Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222 [TBL] [Abstract][Full Text] [Related]
18. Effect of itraconazole on the pharmacokinetics of atorvastatin. Kantola T; Kivistö KT; Neuvonen PJ Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720 [TBL] [Abstract][Full Text] [Related]
19. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357 [TBL] [Abstract][Full Text] [Related]
20. Metabolism and excretion of atorvastatin in rats and dogs. Black AE; Hayes RN; Roth BD; Woo P; Woolf TF Drug Metab Dispos; 1999 Aug; 27(8):916-23. PubMed ID: 10421619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]